共 50 条
The performance of femoropopliteal bypasses using polytetrafluoroethylene above the knee versus autogenous vein below the knee
被引:20
|作者:
Woratyla, SP
[1
]
Darling, C
[1
]
Chang, BB
[1
]
Paty, PSK
[1
]
Kreienberg, PB
[1
]
Leather, RP
[1
]
Shah, DM
[1
]
机构:
[1] ALBANY MED COLL,DEPT SURG A61,VASC SURG SECT,ALBANY,NY 12208
来源:
关键词:
D O I:
10.1016/S0002-9610(97)90077-5
中图分类号:
R61 [外科手术学];
学科分类号:
摘要:
BACKGROUND: Controversy exists as to the choice of conduit for the treatment of superficial femoral artery occlusive disease, particularly when a patent above-knee popliteal artery exists. Some surgeons advocate the preferential use of polytetrafluoroethylene (PTFE), whereas others favor the use of autogenous vein. This report compares our experience with above-knee femoropopliteal bypass with PTFE versus below-knee femoropopliteal bypass with autogenous vein. METHODS: This study covers a 15-year period extending from 1982 to 1996 during which 1,313 arterial reconstructions were performed for superficial femoral and/or proximal popliteal arterial disease. Four hundred and thirty-eight procedures were performed to the above-knee popliteal artery using PTFE, and 875 procedures were performed to the below-knee popliteal artery using autogenous vein. The indication for surgery was limb salvage in 77% of patients in the PTFE group and 88% of patients in the vein group. RESULTS: The 1-, 3-, and 5-year cumulative life table primary patency rates for the PTFE group were 74%, 56%, and 50%, respectively. The primary patency rates for the vein bypass group were 83%, 75%, and 67%, respectively (P < 0.01). The 5-year cumulative limb salvage rates were 91% and 95% for the PTFE and vein groups, respectively (P = NS). CONCLUSIONS: In this series, below-knee femoropopliteal venous reconstructions have superior patency rates compared with above-knee femoropopliteal PTFE reconstructions. Venous reconstruction for femoropopliteal occlusive disease gives the optimal long-term result. Prosthetic reconstruction should be considered for patients with limited venous conduit or decreased life expectancy. (C) 1997 by Excerpta Medica, Inc.
引用
收藏
页码:169 / 172
页数:4
相关论文